# US 2019/0375834 A1 · Disulfide-type hmgb1-specific antibody, method for measuring disulfide-type hmgb1 and kit for said measurement, and measurement method capable of quantitating all of hmgb1 molecules including reduced hmgb1, disulfide-type hmgb1 and thrombin-cleavable hmgb1 and kit for said measurement

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375834 A1
- Document ID: US20190375834A1
- Status: Published application
- Kind: A1
- Application number: 16/345,570
- Filed: 2017-10-19
- Published: 2019-12-12
- Earliest claimed: 2016-10-26
- Assignees: Fuso Pharmaceutical Industries, Ltd.
- Applicants: Fuso Pharmaceutical Industries, Ltd.
- Inventors: Masahiro Asakura; Aya Keshi; Kanako Abe; Nana Sakamoto; Shiho Yamazaki; Hirotsugu Uehara
- Web page: https://patentgrep.com/patent/US20190375834A1

## CPC

- C07K 16/24: against cytokines, lymphokines or interferons
- G01N 33/6875: {Nucleoproteins}
- G01N 33/6863: {Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G01N 2333/52: Assays involving cytokines
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides antibodies that show specific reactivity to disulfide-type HMGB1. Furthermore, the present invention provides methods for specifically measuring disulfide-type HMGB1 using the antibodies, and kits or reagents for the measurement. The present invention also provides methods for measuring total HMGB1 using such an antibody and an antibody that binds to both disulfide-type HMGB1 and reduced-type HMGB1 but does not bind to des-HMGB1, and kits or reagents for the measurement.

## Claims

### Claim 1

An antibody which specifically binds to disulfide-type HMGB1.

### Claim 2 (depends on 1)

The antibody of claim 1, which recognizes an antigenic determinant comprising a disulfide bond formed by cysteines at position 23 (C23) and position 45 (C45) of disulfide-type HMGB1.

### Claim 3 (depends on 1)

The antibody of claim 1, which has neutralizing activity against disulfide-type HMGB1 having activity to bind to MD-2, and/or disulfide-type HMGB1 having cytokine-inducing ability.

### Claim 4 (depends on 1)

The antibody of claim 1, which comprises heavy chain CDR1, CDR2, and CDR3 having the same amino acid sequences as heavy chain CDR1, CDR2, and CDR3 of monoclonal antibody HMa186 produced by a hybridoma identified by accession number NITE BP-02019, and light chain CDR1, CDR2, and CDR3 having the same amino acid sequences as light chain CDR1, CDR2, and CDR3 of monoclonal antibody HMa186 produced by a hybridoma identified by accession number NITE BP-02019, wherein the antibody comprises:
heavy chain CDR1 having the amino acid sequence of SEQ ID NO: 25; heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 27; heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 29;
light chain CDR1 having the amino acid sequence of SEQ ID NO: 31;
and light chain CDR2 having the amino acid sequence of SEQ ID NO: 33.

### Claim 5 (depends on 1)

The antibody of claim 1, which comprises a heavy chain variable region having the same amino acid sequence as the heavy chain variable region of monoclonal antibody HMa186 produced by a hybridoma identified by accession number NITE BP-02019, and a light chain variable region having the same amino acid sequence as the light chain variable region of monoclonal antibody HMa186 produced by a hybridoma identified by accession number NITE BP-02019, wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 47 or 70, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 49 or 72.

### Claim 6

A monoclonal antibody HMa186 produced by a hybridoma identified by accession number NITE BP-02019.

### Claim 7 (depends on 1)

A low-molecular-weight antibody of the antibody of claim 1.

### Claim 8 (depends on 1)

A fragment of the antibody of claim 1, which has specific binding activity to disulfide-type HMGB1.

### Claim 9 (depends on 1)

A chimeric antibody or humanized antibody of the antibody of claim 1.

### Claim 10 (depends on 1)

A human antibody of the antibody of claim 1.

### Claim 11 (depends on 1)

A method for producing a chimeric antibody or humanized antibody of the antibody of claim 1, which comprises the steps of linking a DNA encoding a variable region of the antibody of claim 1 with a DNA encoding a constant region; inserting this into an expression vector; introducing the vector into a host; and producing the variable region and the constant region of the antibody.

### Claim 12 (depends on 1)

A method for measuring or detecting disulfide-type HMGB1 in a sample, which comprises the step of contacting the sample with the antibody of claim 1.

### Claim 13 (depends on 12)

The method of claim 12, wherein measuring or detecting disulfide-type HMGB1 is conducted by an immunological test method.

### Claim at position 14

14-15. (canceled)

### Claim 16 (depends on 1)

A method for measuring or detecting total HMGB1 in a sample, which comprises contacting the sample with the antibodies of (a) and (b) below:
(a) the antibody of claim 1; and
(b) an antibody that binds to both disulfide-type HMGB1 and reduced-type HMGB1 but does not bind to des-HMGB1.

### Claim 17 (depends on 16)

The method of claim 16, wherein total HMGB1 includes disulfide-type HMGB1, reduced-type HMGB1, and thrombin-cleaved HMGB1.

### Claim 18 (depends on 16)

The method of claim 16, wherein the antibody that binds to both disulfide-type HMGB1 and reduced-type HMGB1 but does not bind to des-HMGB1 is an antibody which recognizes an antigenic determinant comprising the amino acid residues between glycine at position 2 (G2) and alanine at position 17 (A17) of disulfide-type HMGB1.

### Claim 19 (depends on 16)

The method of claim 16, wherein the antibody that binds to both disulfide-type HMGB1 and reduced-type HMGB1 but does not bind to des-HMGB1 is an antibody which comprises heavy chain CDR1, CDR2, and CDR3 having the same amino acid sequences as heavy chain CDR1, CDR2, and CDR3 of monoclonal antibody HMa166 produced by a hybridoma identified by accession number NITE BP-02020, and light chain CDR1, CDR2, and CDR3 having the same amino acid sequences as light chain CDR1, CDR2, and CDR3 of monoclonal antibody HMa166 produced by a hybridoma identified by accession number NITE BP-02020, wherein the antibody comprises:
heavy chain CDR1 having the amino acid sequence of SEQ ID NO: 51;
heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 53;
and heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 55.

### Claim 20 (depends on 16)

The method of claim 16, wherein the antibody that binds to both disulfide-type HMGB1 and reduced-type HMGB1 but does not bind to des-HMGB1 is an antibody which comprises a heavy chain variable region having the same amino acid sequence as the heavy chain variable region of monoclonal antibody HMa166 produced by a hybridoma identified by accession number NITE BP-02020, and a light chain variable region having the same amino acid sequence as the light chain variable region of monoclonal antibody HMa166 produced by a hybridoma identified by accession number NITE BP-02020, wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 63 or 74.

### Claim 21 (depends on 16)

The method of claim 16, wherein the antibody that binds to both disulfide-type HMGB1 and reduced-type HMGB1 but does not bind to des-HMGB1 is monoclonal antibody HMa166 produced by a hybridoma identified by accession number NITE BP-02020.

### Claim 22 (depends on 16)

The method of claim 16, wherein measuring or detecting total HMGB1 is conducted by an immunological test method.

### Claim 23 (depends on 1)

A kit or reagent for measuring or detecting total HMGB1 in a sample, which comprises the antibodies of (a) and (b) below:
(a) the antibody of claim 1; and
(b) an antibody that binds to both disulfide-type HMGB1 and reduced-type HMGB1 but does not bind to des-HMGB1.

### Claim 24 (depends on 23)

The kit or reagent of claim 23, wherein total HMGB1 includes disulfide-type HMGB1, reduced-type HMGB1, and thrombin-cleaved HMGB1.

### Claim 25 (depends on 23)

The kit or reagent of claim 23, wherein the antibody that binds to both disulfide-type HMGB1 and reduced-type HMGB1 but does not bind to des-HMGB1 is an antibody which recognizes an antigenic determinant comprising the amino acid residues between glycine at position 2 (G2) and alanine at position 17 (A17) of disulfide-type HMGB1.

### Claim 26 (depends on 23)

The kit or reagent of claim 23, wherein the antibody that binds to both disulfide-type HMGB1 and reduced-type HMGB1 but does not bind to des-HMGB1 is an antibody which comprises heavy chain CDR1, CDR2, and CDR3 having the same amino acid sequences as heavy chain CDR1, CDR2, and CDR3 of monoclonal antibody HMa166 produced by a hybridoma identified by accession number NITE BP-02020, and light chain CDR1, CDR2, and CDR3 having the same amino acid sequences as light chain CDR1, CDR2, and CDR3 of monoclonal antibody HMa166 produced by a hybridoma identified by accession number NITE BP-02020, wherein the antibody comprises:
heavy chain CDR1 having the amino acid sequence of SEQ ID NO: 51; heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 53; and
heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 55.

### Claim 27 (depends on 23)

The kit or reagent of claim 23, wherein the antibody that binds to both disulfide-type HMGB1 and reduced-type HMGB1 but does not bind to des-HMGB1 is an antibody which comprises a heavy chain variable region having the same amino acid sequence as the heavy chain variable region of monoclonal antibody HMa166 produced by a hybridoma identified by accession number NITE BP-02020, and a light chain variable region having the same amino acid sequence as the light chain variable region of monoclonal antibody HMa166 produced by a hybridoma identified by accession number NITE BP-02020, wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 63 or 74.

### Claim 28 (depends on 23)

The kit or reagent of claim 23, wherein the antibody that binds to both disulfide-type HMGB1 and reduced-type HMGB1 but does not bind to des-HMGB1 is monoclonal antibody HMa166 produced by a hybridoma identified by accession number NITE BP-02020.

### Claim 29

(canceled)

### Claim 30

An antibody that binds to both disulfide-type HMGB1 and reduced-type HMGB1 but does not bind to des-HMGB1.

### Claim 31 (depends on 30)

The antibody of claim 30, which recognizes an antigenic determinant comprising the amino acid residues between glycine at position 2 (G2) and alanine at position 17 (A17) of disulfide-type HMGB1.

### Claim 32 (depends on 30)

The antibody of claim 30, which comprises heavy chain CDR1, CDR2, and CDR3 having the same amino acid sequences as heavy chain CDR1, CDR2, and CDR3 of monoclonal antibody HMa166 produced by a hybridoma identified by accession number NITE BP-02020, and light chain CDR1, CDR2, and CDR3 having the same amino acid sequences as light chain CDR1, CDR2, and CDR3 of monoclonal antibody HMa166 produced by a hybridoma identified by accession number NITE BP-02020, wherein the antibody comprises:
heavy chain CDR1 having the amino acid sequence of SEQ ID NO: 51; heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 53; and heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 55.

### Claim 33 (depends on 30)

The antibody of claim 30, which comprises a heavy chain variable region having the same amino acid sequence as the heavy chain variable region of monoclonal antibody HMa166 produced by a hybridoma identified by accession number NITE BP-02020, and a light chain variable region having the same amino acid sequence as the light chain variable region of monoclonal antibody HMa166 produced by a hybridoma identified by accession number NITE BP-02020, wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 63 or 74.

### Claim 34

A monoclonal antibody HMa166 produced by a hybridoma identified by accession number NITE BP-02020.

### Claim 35

A monoclonal antibody CP11-1 produced by a hybridoma identified by accession number NITE BP-02021.
